Logo image of ABVC

ABVC BIOPHARMA INC (ABVC) Stock Price, Forecast & Analysis

USA - NASDAQ:ABVC - US00091F3047 - Common Stock

2.99 USD
+0.1 (+3.46%)
Last: 11/12/2025, 8:00:00 PM

ABVC Key Statistics, Chart & Performance

Key Statistics
Market Cap70.38M
Revenue(TTM)798.00K
Net Income(TTM)-4.12M
Shares23.54M
Float20.78M
52 Week High5.48
52 Week Low0.4
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.22
PEN/A
Fwd PEN/A
Earnings (Next)04-13 2026-04-13/amc
IPO2004-11-09
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ABVC short term performance overview.The bars show the price performance of ABVC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

ABVC long term performance overview.The bars show the price performance of ABVC in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200 300 400

The current stock price of ABVC is 2.99 USD. In the past month the price increased by 3.1%. In the past year, price increased by 498%.

ABVC BIOPHARMA INC / ABVC Daily stock chart

ABVC Latest News, Press Relases and Analysis

3 months ago - By: The Motley Fool

ABVC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 24.68 412.01B
AMGN AMGEN INC 15.38 181.04B
GILD GILEAD SCIENCES INC 15.07 153.12B
VRTX VERTEX PHARMACEUTICALS INC 25.01 111.32B
REGN REGENERON PHARMACEUTICALS 15.15 72.26B
ALNY ALNYLAM PHARMACEUTICALS INC 887.73 59.35B
INSM INSMED INC N/A 41.09B
NTRA NATERA INC N/A 28.75B
BIIB BIOGEN INC 9.65 23.67B
INCY INCYTE CORP 16.86 21.14B
UTHR UNITED THERAPEUTICS CORP 17.49 20.88B
NBIX NEUROCRINE BIOSCIENCES INC 35.13 14.56B

About ABVC

Company Profile

ABVC logo image ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 16 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.

Company Info

ABVC BIOPHARMA INC

44370 Old Warm Springs Blvd

Fremont CALIFORNIA US

CEO: Howard Doong

Employees: 16

ABVC Company Website

ABVC Investor Relations

Phone: 15106680881

ABVC BIOPHARMA INC / ABVC FAQ

Can you describe the business of ABVC BIOPHARMA INC?

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 16 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.


What is the current price of ABVC stock?

The current stock price of ABVC is 2.99 USD. The price increased by 3.46% in the last trading session.


Does ABVC BIOPHARMA INC pay dividends?

ABVC does not pay a dividend.


What is the ChartMill technical and fundamental rating of ABVC stock?

ABVC has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Where is ABVC BIOPHARMA INC (ABVC) stock traded?

ABVC stock is listed on the Nasdaq exchange.


Can you provide the number of employees for ABVC BIOPHARMA INC?

ABVC BIOPHARMA INC (ABVC) currently has 16 employees.


Can you provide the market cap for ABVC BIOPHARMA INC?

ABVC BIOPHARMA INC (ABVC) has a market capitalization of 70.38M USD. This makes ABVC a Micro Cap stock.


ABVC Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ABVC. When comparing the yearly performance of all stocks, ABVC is one of the better performing stocks in the market, outperforming 98.97% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ABVC Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ABVC. Both the profitability and financial health of ABVC have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABVC Financial Highlights

Over the last trailing twelve months ABVC reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 77.08% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -19.44%
ROE -34.14%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%-168%
Sales Q2Q%104.47%
EPS 1Y (TTM)77.08%
Revenue 1Y (TTM)56.53%

ABVC Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y-4.55%
Revenue Next YearN/A

ABVC Ownership

Ownership
Inst Owners1.56%
Ins Owners8.21%
Short Float %2.06%
Short Ratio4.33